Professional Reference articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.
See also the separate article on Human Papillomavirus and Genital Warts.
Human papillomavirus (HPV) vaccination was introduced into the immunisation schedule for females aged 12-13 years in September 2008.
HPV is a double-stranded DNA virus, which infects squamous epithelia, including the skin and mucosae of the upper respiratory and anogenital tracts. There are approximately 100 types of HPV, of which about 40 infect the genital tract. Although most infections are asymptomatic and self-limiting, genital infection by HPV is associated with genital warts and anogenital cancers, both in men and in women. It has also been more recently shown that HPV can cause oropharyngeal cancers, and prevalence of these tumours is rising.
HPV viruses are classified as either 'high-risk' or 'low-risk' types depending on their association with the development of cancer:
- Genital HPVs are transmitted by sexual contact with an infected individual, usually through sexual intercourse.
- The risk increases with the number of sexual partners, the introduction of a new sexual partner or because of the sexual history of a new partner. The use of condoms reduces but does not eliminate the risk of sexual transmission.
- Non-sexual routes of HPV transmission include vertical transmission from mother to newborn baby.
Of the high-risk types, HPV16 and HPV18 are responsible for more than two thirds of all cervical cancers globally.[3, 4]The majority of high-risk HPV infections are transient and cause no clinical problems. Persistent infection by a high-risk HPV type is the most important causal factor for the development of cervical pre-cancerous and cancerous lesions. Persistence and disease are more common for infections by HPV types 16 and 18 than for other high-risk types. The reduction of cervical cancer was the original aim in the widespread introduction of HPV vaccination, but other benefits have rapidly become apparent.
HPV testing is rapidly becoming a part of the cervical cancer screening programmes across the UK as studies have shown the benefits.
Surveillance of HPV is complex due to the high proportion of asymptomatic infections, the variable presentation of the different viral types and the long period between infection and disease.
A UK seroprevalence study in an unselected population showed that HPV prevalence was extremely low in girls aged 14 years but HPV infections rise sharply in the mid-teens.
Prevalence of any HPV type, and particularly of HPV16 or HPV18, is higher in women who have abnormal cytology. HPV is detected in 99% of cervical tumours.
There are two HPV vaccines available in the UK: Cervarix® and Gardasil®.
Cervarix® is known as a bivalent vaccine, meaning it protects against two strains of HPV. Cervarix® protects against HPV16 and HPV18 and so is aimed to reduce (in time) the number of cases of cervical cancer. When the UK first started immunising young women against HPV, this was the vaccine chosen.
Gardasil® is a quadrivalent vaccine, meaning it protects against four strains of HPV. Gardasil® protects against HPV16, HPV18 and HPV6 and HPV11. This means that it also protects against genital warts as well as cervical cancer, as HPV 6 and 11 cause the majority of cases of genital warts.
In November 2011, the Department of Health announced that from September 2012 the UK HPV immunisation programme would switch to using Gardasil®.
HPV vaccines are highly effective at preventing the infection of susceptible women with the HPV types covered by the vaccine. In clinical trials, both vaccines are over 99% effective at preventing pre-cancerous lesions associated with HPV types 16 or 18 in young women.Current studies suggest that protection is maintained for at least ten years.Based on the immune responses, it is expected that protection will be extended further; long-term follow-up studies are in place.
A World Health Organization-funded study on cost-effectiveness of the HPV vaccination across 179 countries showed it was very cost-effective in the majority of countries.Vaccination of 58 million 12-year-old girls in 179 countries had prevented 690,000 cases of cervical cancer and 420,000 deaths.
Gardasil® is also 99% effective at preventing genital warts associated with vaccine types in young women.Australia was the first country to introduce national HPV vaccination with the quadrivalent vaccine, and results after five years from sexual health clinics showed a marked reduction of genital warts in women and also heterosexual men in the vaccinated age group.Between 2007 and 2011, the percentage of women having genital warts in sexual health clinics in the relevant age group dropped from 11.5% to 0.85%. In 2011 no diagnoses of genital warts were made in girls who had been vaccinated. The UK can expect similar reduction, but results will be delayed as the bivalent vaccine was used until 2012.
Administration dosage and schedule
Since the immunisation programme began, on a three-dose schedule, it has been established that a two-dose schedule is as effective as a course of three. From 2014, a two-dose schedule has been recommended, as long as vaccination is started before the girl's 15th birthday. This will start at age 11-13 from September 2014 (school year 8 in England and Wales, 9 in Northern Ireland, S2 in Scotland). For either vaccine, a 0.5 ml dose is given first, with the second 0.5 ml dose given 6-24 months later.
The three-dose schedule for girls over the age of 15 is as follows:
- Schedule for Gardasil®:
- First dose of 0.5 ml.
- Second dose of 0.5 ml at least one month after the first dose.
- Third dose of 0.5 ml at least three months after the second dose.
- Schedule for Cervarix®:
- First dose of 0.5 ml.
- Second dose of 0.5 ml, one to two and a half months after the first dose.
- Third dose of 0.5 ml at least five months after the first dose.
If vaccination has been started before September 2014, if the three-dose schedule has been started, it should be completed as per the schedule above. If the second dose has been given within six months of the first, two doses are not considered to confer adequate long-term immunity. Therefore, a third dose should be given.
Vaccines are given intramuscularly in the upper arm or anterolateral thigh.
HPV immunisation programme cohort
The objective of the HPV immunisation programme is to provide three doses of HPV vaccine to females before they reach an age when the risk of HPV infection increases and they are at subsequent risk of cervical cancer.
Females aged 9 to 11 years
Gardasil® and Cervarix® are licensed for individuals from the age of 9 years. Vaccination is not routinely recommended for those aged 9 to 11 years and is not covered by the national immunisation programme.
Females aged 11 to 18 years
HPV vaccination is routinely recommended for all girls at 11 to 14 years of age with the first dose offered in school year 8 in England and Wales, S1/S2 in Scotland, and school year 9 in Northern Ireland.
If the course is interrupted then it should be resumed but not repeated, ideally allowing the appropriate interval between the remaining doses. For girls who miss starting a course of vaccination in the first target year, those less than 15 years of age should still start on a two-dose schedule. Those aged 15 or less than 18 years of age should start a three-dose schedule.
Females aged 18 or over
Vaccination against HPV is not part of the routine immunisation programme for those aged 18 years or over. However, for those who did not complete their vaccinations during the catch-up programme it is reasonable to do so after the age of 18.
Vaccination of females with unknown or incomplete immunisation status
Where a female in the target cohort aged over 12 and under 18 years presents with an inadequate vaccination history, every effort should be made to clarify what doses they have had. A female who has not completed the schedule should complete the vaccination course at the minimum interval (see above) where possible. Females coming to the UK from overseas may not have been offered protection against HPV in their country of origin and should be offered vaccination where appropriate.
Vaccination of boys
Males of any age are not currently covered by the national immunisation programme. This is currently the subject of much debate and controversy.[2, 12]Gender-neutral vaccination has been recommended in other countries, such as the USA, Canada, Australia and Austria. This is because, although there may be a herd immunity effect in reducing genital warts in heterosexual men, it discriminates against men who have sex with men. It is thought that where both boys and girls are routinely vaccinated this will also help significantly reduce other anogenital and oropharyngeal cancers.
All suspected adverse drug reactions, no matter how minor, should be reported in children under 18 years (even if the black triangle symbol has been removed), using the Yellow Card reporting scheme (www.mhra.gov.uk/yellowcard).
As with most vaccines, the most common side-effect is mild-to-moderate swelling, redness and pain at the site where the injection is given. Other mild side-effects (eg, slightly raised temperature, sickness, dizziness, diarrhoea and muscle aches) have been reported.
Very rarely, as with most vaccines, some people have an allergic reaction or anaphylaxis soon after immunisation.
There have been a few case reports of primary ovarian failure following vaccination, thought to be due to the vaccine triggering an autoimmune condition. Systemic reviews and meta-analyses of the vaccine so far, however, suggest the incidence of serious adverse reactions is insignificant.
Individuals with immunosuppression or with HIV infection should be considered for HPV vaccines. However, individuals who are immunosuppressed may not develop a full antibody response. Three-dose schedules are advised in this group. Re-immunisation should be considered after treatment is finished and/or recovery has occurred. Specialist advice may be required.
Did you find this information useful?
Further reading & references
- Bresse X, Adam M, Largeron N, et al; A comparative analysis of the epidemiological impact and disease cost-savings of HPV vaccines in France. Hum Vaccin Immunother. 2013 Apr 1 9(4).
- Developing role of HPV in cervical cancer prevention; Developing role of HPV in cervical cancer prevention. BMJ. 2013 Aug 20 347:f5207. doi: 10.1136/bmj.f5207.
- Kane MA; Preventing cancer with vaccines: progress in the global control of cancer. Cancer Prev Res (Phila). 2012 Jan 5(1):24-9. doi: 10.1158/1940-6207.CAPR-11-0533.
- Barton S, O'Mahony C; HPV vaccination--reaping the rewards of the appliance of science. BMJ. 2013 Apr 18 346:f2184. doi: 10.1136/bmj.f2184.
- Introduction of Human Papillomavirus Vaccine into the national immunisation programme; Dept of Health, May 2008 (archived content)
- Stanley M; HPV vaccination in boys and men. Hum Vaccin Immunother. 2014 10(7):2109-11. doi: 10.4161/hv.29137.
- Jit M, Vyse A, Borrow R, et al; Prevalence of human papillomavirus antibodies in young female subjects in England. Br J Cancer. 2007 Oct 8 97(7):989-91. Epub 2007 Aug 28.
- Colombo N, Carinelli S, Colombo A, et al; Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012 Oct 23 Suppl 7:vii27-32.
- Arbyn M, Roelens J, Simoens C, et al; Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions. Cochrane Database Syst Rev. 2013 Mar 28 3:CD008054. doi: 10.1002/14651858.CD008054.pub2.
- Lehtinen M, Dillner J; Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol. 2013 Jul 10(7):400-10. doi: 10.1038/nrclinonc.2013.84. Epub 2013 Jun 4.
- Human papillomavirus (HPV): the green book, chapter 18a; Public Health England (June 2014)
- Rana MM, Huhtala H, Apter D, et al; Understanding long-term protection of human papillomavirus vaccination against cervical carcinoma: Cancer registry-based follow-up. Int J Cancer. 2013 Jun 15 132(12):2833-8. doi: 10.1002/ijc.27971. Epub 2012 Dec 19.
- Jit M, Brisson M, Portnoy A, et al; Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. Lancet Glob Health. 2014 Jul 2(7):e406-14. doi: 10.1016/S2214-109X(14)70237-2. Epub 2014 Jun 9.
- Garland SM, Hernandez-Avila M, Wheeler CM, et al; Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007 May 10 356(19):1928-43.
- Ali H, Donovan B, Wand H, et al; Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013 Apr 18 346:f2032. doi: 10.1136/bmj.f2032.
- Stanley M, O'Mahony C, Barton S; HPV vaccination. BMJ. 2014 Jul 29 349:g4783. doi: 10.1136/bmj.g4783.
- British National Formulary
- Zimmerman RK; HPV vaccine and its recommendations, 2007. J Fam Pract. 2007 Feb 56(2 Suppl Vaccines):S1-5, C1.
- Colafrancesco S, Perricone C, Tomljenovic L, et al; Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants. Am J Reprod Immunol. 2013 Oct 70(4):309-16. doi: 10.1111/aji.12151. Epub 2013 Jul 31.
- Lu B, Kumar A, Castellsague X, et al; Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect Dis. 2011 Jan 12 11:13. doi: 10.1186/1471-2334-11-13.
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. Patient Platform Limited has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.